In clinical trials
Digestive & weight
Survodutide
Evidence
Clinical trials
Class
Dual glucagon and GLP-1 receptor agonist
KEY TAKEAWAY
Survodutide is a peptide that activates both the glucagon and GLP-1 receptors. Boehringer Ingelheim is developing it for obesity and fatty liver disease. Survodutide is not FDA-approved and is being tested in late-stage clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Dual glucagon and GLP-1 receptor agonist
Being studied for
Studied for obesity and fatty liver disease (MASH)
Key fact
Survodutide is not FDA-approved and is being tested in late-stage clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Survodutide is a peptide that activates both the glucagon and GLP-1 receptors. Boehringer Ingelheim is developing it for obesity and fatty liver disease.
GLP-1 activity reduces appetite, while glucagon activity may increase energy use and lower fat stored in the liver.
Survodutide is not FDA-approved and is being tested in late-stage clinical trials.
Studied for obesity and fatty liver disease (MASH).
Nausea, vomiting and diarrhea were the most common effects in trials.
Survodutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.